/PRNewswire/ Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T.
AstraZeneca has committed $1.3 billion to acquire CinCor Pharma, a clinical-stage biotech whose lead drug candidate has the potential to treat hypertension in a new way. In other M&A news, Ipsen and Chiesi Farmaceutici each announced acquisitions of rare disease biotechs. All three deals come with contingent value rights.
/PRNewswire/ Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the.
/PRNewswire/ Marengo Therapeutics, Inc., a company pioneering novel therapeutics targeting the T cell receptor Vβ chain (TCR Vβ) to selectively activate the.
Regulatory News: Ipsen (IPNIPSEY, a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third